Gefitinib API (CAS No. 184475-35-2) is a synthetic small-molecule targeted oncology active pharmaceutical ingredient associated with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer pharmaceutical applications.
Gefitinib, also known by the development code ZD1839, belongs to the class of epidermal growth factor receptor tyrosine kinase inhibitors.
The epidermal growth factor receptor is a transmembrane receptor tyrosine kinase involved in cellular growth, proliferation, survival, and differentiation signaling.
Gefitinib inhibits the intracellular tyrosine kinase activity of EGFR. By interfering with EGFR-mediated signaling, Gefitinib reduces downstream cellular signaling pathways associated with tumor-cell proliferation and survival in susceptible EGFR-driven cancer cells.
Gefitinib is particularly associated with targeted pharmaceutical treatment strategies for metastatic non-small cell lung cancer in patients whose tumors contain specific sensitizing EGFR mutations.
Pharmaceutical companies sourcing Gefitinib API commonly evaluate assay, HPLC purity, related substances, process-related impurities, degradation products, residual solvents, water content, crystalline form, particle size distribution, polymorphic characteristics, and batch-to-batch consistency.
Gefitinib is a weakly basic compound with strongly pH-dependent aqueous solubility. Its solubility decreases as pH increases and the material is practically insoluble under higher-pH aqueous conditions. Therefore, crystal form, particle size distribution, dissolution characteristics, and solid-state consistency may be important during oral tablet formulation development.
Impurity-profile control is another important consideration during Gefitinib API qualification. Pharmaceutical buyers may evaluate specified Gefitinib-related compounds, process intermediates, degradation products, residual solvents, and chromatographic purity according to the applicable pharmacopoeial or approved product specification.
Swapnroop Drugs and Pharmaceuticals supplies Gefitinib API for qualified pharmaceutical research, targeted oncology drug development, analytical, generic drug development, oral solid dosage formulation, and regulated manufacturing requirements with product-specific quality documentation, pharmaceutical-grade packaging, and reliable supply-chain coordination.
Pharmaceutical companies evaluating Gefitinib API commonly focus on:
Impurity-profile control is important during Gefitinib API qualification because pharmacopoeial and product-specific specifications may include control of named related compounds and other organic impurities.
Solid-state characteristics are also important because Gefitinib exhibits pH-dependent aqueous solubility. Crystal form, polymorphic consistency, particle size, and dissolution characteristics may influence oral tablet formulation performance.
Gefitinib API is primarily associated with:
Gefitinib pharmaceutical products are associated with first-line treatment of metastatic non-small cell lung cancer in patients whose tumors contain specific EGFR exon 19 deletion or exon 21 L858R substitution mutations.
Gefitinib is a targeted EGFR tyrosine kinase inhibitor associated with molecularly selected non-small cell lung cancer pharmaceutical applications.
Pharmaceutical companies evaluating Gefitinib API may review:
Product-specific API specifications should be evaluated according to the intended oral dosage form, formulation process, target regulatory market, and approved pharmaceutical development requirements.
The epidermal growth factor receptor is a receptor tyrosine kinase involved in intracellular signaling pathways that regulate cell proliferation and survival.
Activation of EGFR can stimulate downstream signaling pathways associated with tumor-cell growth.
Gefitinib inhibits the intracellular tyrosine kinase domain of EGFR.
Gefitinib competes with ATP for binding within the EGFR tyrosine kinase domain and reduces receptor phosphorylation and downstream signaling.
In susceptible EGFR mutation-driven tumor cells, inhibition of EGFR signaling can reduce tumor-cell proliferation and survival.
The targeted activity of Gefitinib is particularly relevant to tumors containing sensitizing EGFR mutations.
Gefitinib is strongly associated with molecularly targeted treatment of EGFR mutation-positive non-small cell lung cancer.
Important EGFR mutations associated with Gefitinib pharmaceutical treatment include:
Molecular testing is an important component of Gefitinib treatment selection in approved clinical use.
Gefitinib API buyers developing targeted oncology products should evaluate the intended regulatory market, reference drug strategy, approved indication, and formulation requirements.
Gefitinib is a weakly basic pharmaceutical compound with pH-dependent aqueous solubility.
Gefitinib demonstrates greater solubility under acidic conditions and decreasing solubility as the pH increases.
The material is practically insoluble under higher-pH aqueous conditions.
This physicochemical characteristic may be relevant during:
Particle size distribution and solid-state characteristics should be controlled according to the approved formulation and product specification.
Gefitinib is associated with oral solid dosage pharmaceutical products.
Formulation-development considerations may include:
Particle-size-controlled or solid-state-specific API requirements should be confirmed according to the intended formulation process and approved product specification.
Swapnroop Drugs and Pharmaceuticals supports qualified pharmaceutical and oncology-development customers with:
Gefitinib API is supplied in secure pharmaceutical-grade packaging selected according to product quantity, stability requirements, moisture protection requirements, and customer specifications.
Product-appropriate inner polyethylene liners and approved pharmaceutical-grade outer containers or HDPE drums may be used according to the supplied material specification.
Available packaging configurations may include:
Packaging configuration, MOQ, commercial quantity, particle size requirements, polymorphic requirements, and shipment conditions are confirmed according to the approved product specification and customer enquiry.
Store Gefitinib API in tightly closed and appropriately labeled containers under the controlled storage conditions specified in the approved product documentation.
Protect the material from excessive moisture, heat, direct light, and unsuitable environmental exposure.
Gefitinib is an antineoplastic pharmaceutical material. Handling should be performed by trained personnel using approved potent-compound and pharmaceutical raw material handling procedures, suitable containment practices, appropriate personal protective equipment, and applicable safety documentation.
Product-specific storage and handling requirements should be confirmed from the approved COA, SDS, specification, and stability documentation.
Get Bulk Quote via WhatsApp